Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | INCA00186 |
Trade Name | |
Synonyms | INCA 00186|INCA-00186 |
Drug Descriptions |
INCA00186 is a humanized monoclonal antibody that binds to and inhibits CD73, potentially leading to enhanced anti-tumor immune response and inhibition of tumor growth (Cancer Res 2021;81(13_Suppl):Abstract nr LB174). |
DrugClasses | CD73 Antibody 12 |
CAS Registry Number | NA |
NCIT ID | C182010 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
INCA00186 | INCA00186 | 0 | 1 |
INCA00186 + INCB106385 | INCA00186 INCB106385 | 0 | 1 |
INCA00186 + INCB106385 + Retifanlimab | INCA00186 INCB106385 Retifanlimab | 0 | 1 |
INCA00186 + Retifanlimab | INCA00186 Retifanlimab | 0 | 1 |